PMID- 31466903
OWN - NLM
STAT- MEDLINE
DCOM- 20200722
LR  - 20200722
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 71
DP  - 2020 Jan
TI  - The efficacy and safety of lamotrigine for absence seizures in children and 
      adolescents: A systematic review and meta-analysis.
PG  - 199-204
LID - S0967-5868(19)31268-8 [pii]
LID - 10.1016/j.jocn.2019.08.043 [doi]
AB  - AIMS: This systematic review and meta-analysis of randomized controlled trials 
      (RCTs) systematically explored the effectiveness and safety of lamotrigine for 
      absence seizures in children and adolescents. METHODS: Keywords searches were 
      conducted in Pubmed Embase Cochrane Central Register of Controlled Trials Wanfang 
      CNKI from inception through March 2019. The RCTs comparing lamotrigine with other 
      drugs and/or placebo for the treatment of absence seizures in children and 
      adolescents were considered in this study. The study was conducted adhering to 
      PRISMA guidelines. RESULTS: Eight RCTs (n = 787) were included in our study. 
      Among these studies, one study (N = 45 patients) used placebo as a control and 
      seven studies (N = 742 patients) used positive drug controls. For effectiveness, 
      there was significant difference between lamotrigine and valproate [OR = 0.42, 
      95%CI (0.28-0.63), I(2) = 0%] or ethosuximide [OR = 0.34, 95%CI (0.22-0.53), 
      I(2) = 0%]. For adverse effects (AEs), there was no significant difference 
      between lamotrigine and valproate [OR = 1.17, 95%CI (0.59, 2.32), I(2) = 0%] or 
      ethosuximide [OR = 0.75, 95%CI (0.47, 1.19), I(2) = 92%], and the most common 
      adverse effects of lamotrigine were Rash (7.88%), Fatigue (6.50%) and Headache 
      (6.50%). CONCLUSIONS: According to current evidence, LTG is less effective than 
      VPA and ESM, however, based on its relative safety, LTG might be reasonably tried 
      as initial therapy in children and adolescents at risk of significant adverse 
      effects from VPA and ESM, and future well-designed studies are needed to confirm 
      our findings.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Cao, Jing
AU  - Cao J
AD  - Department of Traditional Chinese Medicine, Beijing Tiantan Hospital, Capital 
      Medical University, Beijing, China.
FAU - Lin, Xiao-Xiao
AU  - Lin XX
AD  - Affiliated Hangzhou First People's Hospital, Zhejiang University School of 
      Medicine, Hangzhou, China; Nanjing Medical University, Nanjing, China.
FAU - Ma, Xiang-Ming
AU  - Ma XM
AD  - The First Hospital of Lanzhou, Lanzhou, China.
FAU - Liu, Huanzhong
AU  - Liu H
AD  - Chaohu Hospital of Anhui Medical University, Anhui, China. Electronic address: 
      drhuanzhongliu@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190826
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Anticonvulsants)
RN  - U3H27498KS (Lamotrigine)
SB  - IM
MH  - Adolescent
MH  - Anticonvulsants/*therapeutic use
MH  - Child
MH  - Epilepsy, Absence/*drug therapy
MH  - Female
MH  - Humans
MH  - Lamotrigine/*therapeutic use
MH  - Male
MH  - Seizures/drug therapy
OTO - NOTNLM
OT  - Absence seizures
OT  - Children and adolescents
OT  - Efficacy
OT  - Lamotrigine
OT  - Meta-analysis
COIS- Declaration of Competing Interest The authors declare that they have no conflict 
      of interest related to this work.
EDAT- 2019/08/31 06:00
MHDA- 2020/07/23 06:00
CRDT- 2019/08/31 06:00
PHST- 2019/06/30 00:00 [received]
PHST- 2019/08/05 00:00 [accepted]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2020/07/23 06:00 [medline]
PHST- 2019/08/31 06:00 [entrez]
AID - S0967-5868(19)31268-8 [pii]
AID - 10.1016/j.jocn.2019.08.043 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Jan;71:199-204. doi: 10.1016/j.jocn.2019.08.043. Epub 2019 
      Aug 26.